About: Detection of antibodies to the SARS-CoV-2 spike glycoprotein in both serum and saliva enhances detection of infection

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Detection of antibodies to the SARS-CoV-2 spike glycoprotein in both serum and saliva enhances detection of infection Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Detection of antibodies to the SARS-CoV-2 spike glycoprotein in both serum and saliva enhances detection of infection
Creator	Crispin, Max Watanabe, Yasunori Goodall, Margaret Allen, Joel Cook, Alex Drayson, Mark O'shea, Matthew Cunningham, Adam Faustini, Sian Jossi, Sian Morley, Gabriella Newby, Maddy Perez-Toledo, Marisol Plant, Tim Richter, Alex Shields, Adrian Veenith, Tonny Wraith, David Ponsford, Mark Harding, Stephen Heaney, Jennifer Huissoon, Aarnoud Jolles, Stephen Marcial-Juarez, Edith Salim, Mahboob Torlinska, Barbara Willcox, Benjamin Willcox, Carrie
source	MedRxiv; Medline; PMC
abstract	BACKGROUND: Detecting antibody responses during and after SARS-CoV-2 infection is essential in determining the seroepidemiology of the virus and the potential role of antibody in disease. Scalable, sensitive and specific serological assays are essential to this process. The detection of antibody in hospitalized patients with severe disease has proven straightforward; detecting responses in subjects with mild disease and asymptomatic infections has proven less reliable. We hypothesized that the suboptimal sensitivity of antibody assays and the compartmentalization of the antibody response may contribute to this effect. METHODS: We systemically developed an ELISA assay, optimising different antigens and amplification steps, in serum and saliva from symptomatic and asymptomatic SARS-CoV-2-infected subjects. RESULTS: Using trimeric spike glycoprotein, rather than nucleocapsid enabled detection of responses in individuals with low antibody responses. IgG1 and IgG3 predominate to both antigens, but more antispike IgG1 than IgG3 was detectable. All antigens were effective for detecting responses in hospitalized patients. Anti-spike, but not nucleocapsid, IgG, IgA and IgM antibody responses were readily detectable in saliva from non-hospitalized symptomatic and asymptomatic individuals. Antibody responses in saliva and serum were largely independent of each other and symptom reporting. CONCLUSIONS. Detecting antibody responses in both saliva and serum is optimal for determining virus exposure and understanding immune responses after SARS-CoV-2 infection. FUNDING. This work was funded by the University of Birmingham, the National Institute for Health Research (UK), the NIH National Institute for Allergy and Infectious Diseases, the Bill and Melinda Gates Foundation and the University of Southampton.
has issue date	2020-06-18(xsd:dateTime)
bibo:doi	10.1101/2020.06.16.20133025
bibo:pmid	32588002
has license	cc-by
sha1sum (hex)	e2d694ac46fe36cd29778136da49493549d24fa5
schema:url	https://doi.org/10.1101/2020.06.16.20133025
resource representing a document's title	Detection of antibodies to the SARS-CoV-2 spike glycoprotein in both serum and saliva enhances detection of infection
has PubMed Central identifier	PMC7310662
has PubMed identifier	32588002
schema:publication	medRxiv
resource representing a document's body	covid:e2d694ac46fe36cd29778136da49493549d24fa5#body_text
is schema:about of	named entity 'assays' named entity 'detection' named entity 'proven' named entity 'infections' named entity 'infection' named entity 'infection' covid:arg/e2d694ac46fe36cd29778136da49493549d24fa5 named entity 'sensitivity' named entity 'responses' named entity 'compartmentalization' named entity 'sensitive and specific' named entity 'seroepidemiology' named entity 'Scalable' named entity 'infection' named entity 'SARS-CoV-2' named entity 'glycoprotein' named entity 'serum' named entity 'antibody' named entity 'CC-BY 4.0 International license' named entity 'sensitive and specific' named entity 'antibodies' named entity 'cross-reactive' named entity 'saliva' named entity 'SARS-CoV-2' named entity 'infection' named entity 'pathogen' named entity 'pathogenesis' named entity 'saliva' named entity 'antibodies' named entity 'upper respiratory tract infections' named entity 'antibody' named entity 'viral entry' named entity 'antibodies' named entity 'IgA' named entity 'oral cavity' named entity 'saliva' named entity 'SARS-CoV-2' named entity 'peer review' named entity 'glycan' named entity 'IgG2' named entity 'saliva' named entity 'immunoassay' named entity 'pathogens' named entity 'medRxiv' named entity 'preprint' named entity 'human pathogen' named entity 'nucleocapsid' named entity 'infection' named entity 'glycoprotein' named entity 'IgG subclasses' named entity 'nucleocapsid' named entity 'signal:noise' named entity 'antibody' named entity 'upper respiratory tract'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software